Public Lecture: Equity Considerations of AIDS Vaccine Research in India.

[Guest guest]

INVITATION: Public Lecture

Equity Considerations of AIDS Vaccine Research in India.

By Dr. Joe

You are invited to a lively discussion on the goals and objectives

of Indian AIDS Vaccine research agenda. An effective AIDS Vaccine

(preventive and theraputic) could provide us with an additional tool

to fight the pandemic. But, have we got our AIDS Vaccine research

strategy correct?

What should be the criteria for selecting an AIDS vaccine trial

candidate is neither a rhetorical question nor a value-neutral

assumption. It is a question of life and death. But the question we

tend to forget is, who's life and who's death we are talking about?

Selection of an AIDS vaccine candidate should not be based on bio-

medical considerations alone. Health equity considerations must also

be taken into consideration in selecting an AIDS vaccine candidates

and the vaccine research strategy.

By presenting a comparative analysis, Dr. would argue that

therapeutic AIDS vaccine research has a greater equity value over a

preventive AIDS vaccine research in the Indian context. An exclusive

reliance on a preventive AIDS vaccine research will have a serious

opportunity cost. In the long run that would also compromise the

AIDS research capacity of the country. GoI should present a white

paper on AIDS Vaccine research in India and establish an independent

authority to protect the best interest of the clinical trial

participants.

Date: February 23rd 2005 (Followed by Dinner).

Venue:

Conference Room No.I

India International Centre (IIC) New Delhi

India International Centre

40, Max Mueller Marg, New Delhi - 110003

http://www.iicdelhi.nic.in/

Organized by: ActionAid International -India

RSVP by E-MAIL: Sunil Sharma " <sunils@...>

Tel: - 41640571 to 576